Eslikarbazepin asetat: Perbedaan antara revisi

Konten dihapus Konten ditambahkan
Muhammad Anas Sidik (bicara | kontrib)
←Membuat halaman berisi '{{Drugbox | image = Eslicarbazepine acetate structure.svg | image_class = skin-invert-image | width = 175 <!--Clinical data--> | tradename = Aptiom, Zebinix, Exalief | Drugs.com = {{drugs.com|monograph|eslicarbazepine-acetate}} | pregnancy_AU = D | pregnancy_AU_comment = <ref name="Zebinix APM summary" /> | pregnancy_category = | licence_EU = yes | routes_of_administration = Oral | ATC_prefix = N03 | ATC_suffix = AF04 | ATC_suppl...'
Tag: tanpa kategori [ * ] Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan
 
Muhammad Anas Sidik (bicara | kontrib)
Tidak ada ringkasan suntingan
Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan
Baris 40:
| bioavailability =
| protein_bound = ~30%<ref>{{cite book|title=Arzneistoff-Profile| veditors = Dinnendahl V, Fricke U |publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|date=2011|edition=25|volume=4|isbn=978-3-7741-9846-3|language=German}}</ref>
| metabolism = [[UDP-glucuronosyltransferaseGlukuronosiltransferase|UGT]] (?)
| metabolites = Eslicarbazepine (active), [[glucuronide]]s (inactive), etc.
| elimination_half-life = 10–20 jam
Baris 65:
}}
 
'''Eslikarbazepin asetat''' (disingkat '''ESL'''), yang dijual dengan merek dagang Aptiom dan Zebinix, adalah obat antikonvulsan yang disetujui untuk digunakan di Eropa dan Amerika Serikat sebagai monoterapi atau sebagai terapi tambahan untuk [[epilepsi]] dengan kejang[[sawan]] parsial.<ref name="FDA">{{cite news|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm374358.htm|title=FDA approves Aptiom to treat seizures in adults|publisher=[[US FDA]]|date=8 November 2013|access-date=16 December 2019|archive-date=11 January 2017|archive-url=https://web.archive.org/web/20170111161034/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm374358.htm|url-status=dead}}</ref><ref name="Zebinix EPAR">{{cite web | title=Zebinix EPAR | website=[[European Medicines Agency]] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix | access-date=21 January 2021}}</ref><ref name="Aptiom FDA label">{{cite web | title=Aptiom- eslicarbazepine acetate tablet Aptiom- eslicarbazepine acetate kit | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3 | access-date=21 January 2021}}</ref>
 
Mirip dengan [[okskarbazepin]], ESL berfungsi sebagai obat pendahulu (''S'')-(+)-[[likarbazepin]].<ref name="pmid16621450">{{cite journal | vauthors = Rogawski MA | title = Diverse mechanisms of antiepileptic drugs in the development pipeline | journal = Epilepsy Research | volume = 69 | issue = 3 | pages = 273–94 | date = June 2006 | pmid = 16621450 | pmc = 1562526 | doi = 10.1016/j.eplepsyres.2006.02.004 }}</ref> Dengan demikian, [[mekanisme aksi|mekanisme kerja]] keduanya identik.<ref name="pmid15208697">{{cite journal | vauthors = Rogawski MA, Löscher W | title = The neurobiology of antiepileptic drugs | journal = Nature Reviews. Neuroscience | volume = 5 | issue = 7 | pages = 553–64 | date = July 2004 | pmid = 15208697 | doi = 10.1038/nrn1430 | s2cid = 2201038 | url = https://zenodo.org/record/1233562 }}</ref>